The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialA. Huijbers, Wilma E. Mesker, Rob A.�E.�M. Tollenaar et al.|Annals of Oncology|2012Cited by 348
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendationsGabi W. van Pelt, Wilma E. Mesker, Sanne Kjær‐Frifeldt et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2018Cited by 188
Linkage-Specific <i>in Situ</i> Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded TissuesStephanie Holst, Manfred Wuhrer, Bram Heijs et al.|Analytical Chemistry|2016Cited by 185
The tumour–stroma ratio in colon cancer: the biological role and its prognostic impactGabi W. van Pelt, Wilma E. Mesker, Rob A.�E.�M. Tollenaar et al.|Histopathology|2018Cited by 161
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)Tim Dekker, Wilma E. Mesker, Cornelis J.�H. van de Velde et al.|Breast Cancer Research and Treatment|2013Cited by 155